Your session is about to expire
← Back to Search
Procedure
Ablative Therapy for Oligoprogressive Cancer (VALOROUS Trial)
N/A
Recruiting
Led By Xiao Zhao, MD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age ≥18 years at time of consent.
≤ 5 progressing or new metastatic lesions.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months from the first day of ablative local therapy
Awards & highlights
VALOROUS Trial Summary
This trial studies the effectiveness of adding localized treatments to systemic therapy for solid tumors that have not spread widely. The results will measure how long treatment lasts.
Who is the study for?
Adults over 18 with certain cancers (like breast, gynecological, head and neck, sarcomas) who have up to 5 new or worsening metastatic lesions. They must be on systemic therapy they can continue post-treatment and have seen benefits from it for at least 3 months. Not eligible if they have progressing brain tumors or health issues that rule out local therapies.Check my eligibility
What is being tested?
The VALOROUS trial is testing whether adding local ablative treatments (like radiation) to ongoing systemic cancer therapy helps control the disease better in patients whose cancer has started to progress again but only in a limited number of spots.See study design
What are the potential side effects?
While specific side effects are not listed here, generally, local ablative therapies like radiation may cause skin irritation, fatigue, mild pain or discomfort at the treatment site. The exact side effects depend on the area being treated.
VALOROUS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I have 5 or fewer new or growing cancer spots.
Select...
My cancer is confirmed to be in the urinary-genital area.
Select...
I have cancer in my head or neck.
VALOROUS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months from the first day of ablative local therapy
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months from the first day of ablative local therapy
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Disease control
Secondary outcome measures
Grade ≥ 3 adverse events
Median overall survival
Time to treatment failure
VALOROUS Trial Design
1Treatment groups
Experimental Treatment
Group I: Ablative local therapyExperimental Treatment1 Intervention
Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
Find a Location
Who is running the clinical trial?
University of California, DavisLead Sponsor
914 Previous Clinical Trials
4,720,465 Total Patients Enrolled
1 Trials studying Sarcoma
8 Patients Enrolled for Sarcoma
National Cancer Institute (NCI)NIH
13,719 Previous Clinical Trials
40,963,283 Total Patients Enrolled
456 Trials studying Sarcoma
230,439 Patients Enrolled for Sarcoma
Xiao Zhao, MDPrincipal InvestigatorUniversity of California, Davis
Share this study with friends
Copy Link
Messenger